<DOC>
	<DOCNO>NCT02266485</DOCNO>
	<brief_summary>Investigation pharmacodynamics ( inhibition oxidosqualene cyclase , MES marker ) , effect routine lipid profile parameter , safety preliminary pharmacokinetics</brief_summary>
	<brief_title>Pharmacodynamics , Preliminary Pharmacokinetics Tolerability BIBB 515 BS Pravastatin Hyperlipemic Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pravastatin</mesh_term>
	<criteria>Healthy male caucasian subject determine result screen Written informed consent accordance good clinical practice ( GCP ) local legislation give Age ≥ 18 ≤ 65 year Broca ≥ 20 % ≤ + 30 % Cholesterol level ≥ 5.4 mmol/l Any finding medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurologic disorder History orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) ( ≤ 1 month prior administration trial ) Use drug might influence result trial ( ≤ 10 day prior administration trial ) Participation another trial investigational drug ( ≤ 2 month prior administration trial ) Smoker ( &gt; 10 cigarette 3 cigar 3 pipes/day ) Inability refrain smoke study day Alcohol abuse ( &gt; 60 g/day ) Drug abuse Blood donation &gt; 100 ml ( ≤ 4 week prior administration trial ) Excessive physical activity ( ≤ 10 day prior administration trial ) Any laboratory value outside reference range clinical relevance Abnormal finding eye lens examination</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>